Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  2. 7

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  3. 8

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  4. 9

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
소아쌤

ST Pharm to export W152b API to Gilead Ireland

By 황유미

Published : Sept. 19, 2016 - 15:05

    • Link copied

[THE INVESTOR] ST Pharm announced on Sept. 19 that it has signed a 152 billion won (US$135.50 million) contract with Gilead Sciences Ireland to supply anti-viral active pharmaceutical ingredient for hepatitis C treatment.

ST Pharm has been providing the ingredient to Gilead Sciences -- a US-based pharmaceutical company -- that manufactures Sovaldi and Harvoni, treatments for hepatitis C.

The contract amounts to 110 percent of the South Korean company’s revenue last year and the contract lasts from Jan. 1 to Nov. 30, 2017.

ST Pharm is a contract manufacturing organization unit of pharmaceutical heavyweight Dong-A Socio Group, and its revenue from exporting active ingredients for Gilead’s hepatitis C drugs accounted for about 60 percent of its total revenue of 138 billion won in 2015. It went public in June.

By Hwang You-mee (glamazon@heraldcorp.com)

More from Headlines